Brian Lee Claggett, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 371 | 2024 | 11595 | 12.560 |
Why?
|
| Stroke Volume | 279 | 2024 | 5461 | 9.160 |
Why?
|
| Tetrazoles | 86 | 2024 | 899 | 6.430 |
Why?
|
| Angiotensin Receptor Antagonists | 94 | 2024 | 1016 | 6.180 |
Why?
|
| Biphenyl Compounds | 97 | 2024 | 988 | 5.330 |
Why?
|
| Ventricular Function, Left | 128 | 2024 | 3858 | 4.620 |
Why?
|
| Spironolactone | 41 | 2024 | 410 | 3.960 |
Why?
|
| Ventricular Dysfunction, Left | 45 | 2024 | 2115 | 3.530 |
Why?
|
| Drug Combinations | 85 | 2024 | 2020 | 3.450 |
Why?
|
| Glucosides | 24 | 2024 | 498 | 2.900 |
Why?
|
| Enalapril | 27 | 2022 | 311 | 2.850 |
Why?
|
| Benzhydryl Compounds | 32 | 2024 | 900 | 2.770 |
Why?
|
| Natriuretic Peptide, Brain | 52 | 2024 | 1704 | 2.690 |
Why?
|
| Influenza Vaccines | 21 | 2024 | 759 | 2.610 |
Why?
|
| Neprilysin | 31 | 2024 | 471 | 2.410 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 42 | 2024 | 1503 | 2.190 |
Why?
|
| Influenza, Human | 23 | 2024 | 1516 | 2.180 |
Why?
|
| Hospitalization | 73 | 2024 | 10634 | 1.590 |
Why?
|
| Peptide Fragments | 44 | 2024 | 5095 | 1.570 |
Why?
|
| Myocardial Infarction | 34 | 2024 | 11422 | 1.370 |
Why?
|
| Aged | 291 | 2024 | 167890 | 1.330 |
Why?
|
| Diabetes Mellitus, Type 2 | 44 | 2024 | 12078 | 1.320 |
Why?
|
| Cardiovascular Diseases | 57 | 2024 | 15398 | 1.290 |
Why?
|
| Atherosclerosis | 26 | 2024 | 3401 | 1.270 |
Why?
|
| Cardiomyopathy, Hypertrophic | 10 | 2024 | 1309 | 1.230 |
Why?
|
| Echocardiography | 41 | 2024 | 4963 | 1.210 |
Why?
|
| Randomized Controlled Trials as Topic | 36 | 2024 | 10135 | 1.200 |
Why?
|
| Humans | 540 | 2024 | 757566 | 1.170 |
Why?
|
| Renal Insufficiency, Chronic | 21 | 2024 | 2237 | 1.160 |
Why?
|
| Pulmonary Edema | 7 | 2024 | 408 | 1.090 |
Why?
|
| Blood Pressure | 29 | 2023 | 8453 | 1.080 |
Why?
|
| Double-Blind Method | 67 | 2024 | 12261 | 1.060 |
Why?
|
| Data Interpretation, Statistical | 9 | 2021 | 2687 | 1.060 |
Why?
|
| Male | 338 | 2024 | 358180 | 1.040 |
Why?
|
| Urea | 9 | 2024 | 444 | 1.030 |
Why?
|
| Atrial Fibrillation | 22 | 2024 | 5105 | 1.020 |
Why?
|
| Diabetes Mellitus | 21 | 2024 | 5815 | 1.000 |
Why?
|
| Middle Aged | 249 | 2024 | 219192 | 0.990 |
Why?
|
| Female | 338 | 2024 | 389943 | 0.980 |
Why?
|
| Prognosis | 96 | 2024 | 29488 | 0.960 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 15 | 2024 | 431 | 0.940 |
Why?
|
| Treatment Outcome | 115 | 2024 | 64242 | 0.920 |
Why?
|
| Glomerular Filtration Rate | 21 | 2024 | 2152 | 0.890 |
Why?
|
| Naphthyridines | 4 | 2024 | 139 | 0.870 |
Why?
|
| Troponin T | 10 | 2022 | 761 | 0.870 |
Why?
|
| Heart Ventricles | 17 | 2024 | 3806 | 0.860 |
Why?
|
| Heart Failure, Diastolic | 5 | 2024 | 76 | 0.850 |
Why?
|
| Endpoint Determination | 6 | 2019 | 590 | 0.830 |
Why?
|
| Hypertension | 23 | 2023 | 8502 | 0.800 |
Why?
|
| Aged, 80 and over | 97 | 2024 | 58558 | 0.760 |
Why?
|
| Ramipril | 9 | 2024 | 96 | 0.740 |
Why?
|
| Atrial Function, Left | 7 | 2021 | 184 | 0.740 |
Why?
|
| Heart Atria | 13 | 2022 | 1344 | 0.720 |
Why?
|
| Risk Factors | 106 | 2024 | 73708 | 0.710 |
Why?
|
| Troponin I | 5 | 2024 | 632 | 0.700 |
Why?
|
| Cause of Death | 25 | 2024 | 3667 | 0.680 |
Why?
|
| Vaccination | 19 | 2024 | 3354 | 0.670 |
Why?
|
| Prospective Studies | 90 | 2024 | 54092 | 0.670 |
Why?
|
| Hematinics | 7 | 2023 | 280 | 0.670 |
Why?
|
| Antihypertensive Agents | 13 | 2023 | 2018 | 0.660 |
Why?
|
| Acute Coronary Syndrome | 10 | 2023 | 2181 | 0.650 |
Why?
|
| Hyperkalemia | 8 | 2023 | 232 | 0.650 |
Why?
|
| Prealbumin | 7 | 2024 | 222 | 0.650 |
Why?
|
| Hypotension | 7 | 2024 | 880 | 0.620 |
Why?
|
| Risk Assessment | 43 | 2024 | 23816 | 0.620 |
Why?
|
| Cardiomyopathies | 9 | 2024 | 1945 | 0.610 |
Why?
|
| Heart Failure, Systolic | 4 | 2023 | 135 | 0.610 |
Why?
|
| Benzimidazoles | 6 | 2020 | 855 | 0.610 |
Why?
|
| Hypertrophy, Left Ventricular | 9 | 2022 | 849 | 0.600 |
Why?
|
| Proportional Hazards Models | 29 | 2024 | 12397 | 0.590 |
Why?
|
| Hypoglycemic Agents | 13 | 2024 | 3069 | 0.580 |
Why?
|
| Death, Sudden, Cardiac | 7 | 2024 | 1553 | 0.570 |
Why?
|
| Stroke | 19 | 2023 | 9695 | 0.560 |
Why?
|
| Natriuretic Peptides | 8 | 2023 | 155 | 0.560 |
Why?
|
| Ventricular Remodeling | 12 | 2024 | 1256 | 0.550 |
Why?
|
| Life Expectancy | 3 | 2018 | 1238 | 0.540 |
Why?
|
| Exercise Test | 6 | 2024 | 2121 | 0.540 |
Why?
|
| Exercise Tolerance | 6 | 2024 | 830 | 0.540 |
Why?
|
| Anemia | 7 | 2024 | 1503 | 0.530 |
Why?
|
| Kidney | 17 | 2024 | 7012 | 0.520 |
Why?
|
| Echocardiography, Doppler | 11 | 2020 | 898 | 0.510 |
Why?
|
| Amyloid Neuropathies, Familial | 3 | 2023 | 150 | 0.500 |
Why?
|
| Kidney Failure, Chronic | 9 | 2024 | 2455 | 0.500 |
Why?
|
| Time Factors | 46 | 2024 | 39811 | 0.500 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2018 | 850 | 0.490 |
Why?
|
| Quality of Life | 23 | 2024 | 13263 | 0.480 |
Why?
|
| Research Design | 9 | 2023 | 6152 | 0.450 |
Why?
|
| Angiotensins | 7 | 2024 | 143 | 0.440 |
Why?
|
| Hypokalemia | 5 | 2019 | 152 | 0.440 |
Why?
|
| Prediabetic State | 4 | 2022 | 547 | 0.430 |
Why?
|
| Ventricular Dysfunction, Right | 4 | 2023 | 615 | 0.420 |
Why?
|
| Follow-Up Studies | 49 | 2024 | 39020 | 0.420 |
Why?
|
| Survival Rate | 27 | 2022 | 12684 | 0.420 |
Why?
|
| Diastole | 11 | 2023 | 781 | 0.420 |
Why?
|
| Incidence | 36 | 2024 | 21217 | 0.410 |
Why?
|
| Diabetic Angiopathies | 4 | 2020 | 802 | 0.410 |
Why?
|
| Sex Factors | 22 | 2024 | 10495 | 0.410 |
Why?
|
| Diuretics | 7 | 2023 | 610 | 0.410 |
Why?
|
| Proteomics | 6 | 2024 | 3809 | 0.400 |
Why?
|
| Polypharmacy | 3 | 2024 | 305 | 0.390 |
Why?
|
| Coronary Disease | 7 | 2023 | 5915 | 0.370 |
Why?
|
| Defibrillators, Implantable | 5 | 2021 | 1487 | 0.370 |
Why?
|
| Kaplan-Meier Estimate | 14 | 2024 | 6470 | 0.360 |
Why?
|
| Adrenergic beta-Antagonists | 6 | 2023 | 1240 | 0.360 |
Why?
|
| Longitudinal Studies | 13 | 2023 | 14473 | 0.360 |
Why?
|
| Rectal Neoplasms | 1 | 2019 | 1154 | 0.350 |
Why?
|
| Health Status | 9 | 2024 | 4066 | 0.350 |
Why?
|
| Coronary Artery Disease | 9 | 2023 | 6364 | 0.340 |
Why?
|
| Mortality | 9 | 2024 | 2882 | 0.340 |
Why?
|
| Erythropoietin | 3 | 2023 | 719 | 0.340 |
Why?
|
| Systole | 10 | 2023 | 935 | 0.340 |
Why?
|
| Diabetic Nephropathies | 5 | 2023 | 973 | 0.330 |
Why?
|
| United States | 59 | 2024 | 71902 | 0.330 |
Why?
|
| Blood Glucose | 11 | 2024 | 6349 | 0.330 |
Why?
|
| Benzylamines | 6 | 2024 | 247 | 0.330 |
Why?
|
| Heart-Assist Devices | 5 | 2022 | 1279 | 0.330 |
Why?
|
| Survival Analysis | 12 | 2022 | 10075 | 0.330 |
Why?
|
| Uracil | 6 | 2024 | 207 | 0.320 |
Why?
|
| Amyloidosis | 3 | 2024 | 817 | 0.310 |
Why?
|
| Death, Sudden | 3 | 2022 | 302 | 0.300 |
Why?
|
| Biometry | 1 | 2011 | 560 | 0.300 |
Why?
|
| Peptides | 7 | 2023 | 4338 | 0.300 |
Why?
|
| Thiazolidinediones | 1 | 2011 | 461 | 0.290 |
Why?
|
| Predictive Value of Tests | 21 | 2024 | 15207 | 0.290 |
Why?
|
| Renal Dialysis | 5 | 2023 | 1786 | 0.290 |
Why?
|
| Laparoscopy | 1 | 2019 | 2032 | 0.290 |
Why?
|
| Propanolamines | 2 | 2018 | 162 | 0.290 |
Why?
|
| Atrial Function, Right | 2 | 2018 | 32 | 0.290 |
Why?
|
| Neoplasms | 10 | 2023 | 21986 | 0.280 |
Why?
|
| Heart | 6 | 2023 | 4382 | 0.280 |
Why?
|
| Heart Rate | 8 | 2023 | 4172 | 0.280 |
Why?
|
| Cohort Studies | 31 | 2024 | 41190 | 0.280 |
Why?
|
| Kidney Diseases | 4 | 2023 | 2082 | 0.270 |
Why?
|
| Europe | 11 | 2023 | 3413 | 0.270 |
Why?
|
| Clinical Trials as Topic | 10 | 2024 | 7982 | 0.260 |
Why?
|
| Gastrointestinal Agents | 2 | 2021 | 508 | 0.260 |
Why?
|
| Sex Characteristics | 5 | 2023 | 2621 | 0.260 |
Why?
|
| Immunotherapy | 2 | 2018 | 4641 | 0.250 |
Why?
|
| Obesity | 13 | 2022 | 12870 | 0.250 |
Why?
|
| Smoking | 8 | 2021 | 9036 | 0.250 |
Why?
|
| Furosemide | 3 | 2023 | 170 | 0.250 |
Why?
|
| Thrombolytic Therapy | 2 | 2023 | 2060 | 0.250 |
Why?
|
| Sample Size | 5 | 2017 | 838 | 0.250 |
Why?
|
| Intestinal Mucosa | 5 | 2020 | 3021 | 0.250 |
Why?
|
| Denmark | 6 | 2024 | 758 | 0.250 |
Why?
|
| Crohn Disease | 4 | 2021 | 2275 | 0.250 |
Why?
|
| Cardiovascular Agents | 2 | 2024 | 839 | 0.250 |
Why?
|
| Recurrence | 7 | 2024 | 8426 | 0.240 |
Why?
|
| Albuminuria | 5 | 2023 | 650 | 0.240 |
Why?
|
| Comorbidity | 17 | 2021 | 10477 | 0.240 |
Why?
|
| Clinical Trials Data Monitoring Committees | 1 | 2024 | 25 | 0.230 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 2017 | 1111 | 0.230 |
Why?
|
| Coronary Stenosis | 2 | 2020 | 793 | 0.230 |
Why?
|
| Extracellular Matrix | 3 | 2020 | 1722 | 0.220 |
Why?
|
| Heart Arrest | 6 | 2019 | 1494 | 0.220 |
Why?
|
| Adult | 55 | 2024 | 219725 | 0.220 |
Why?
|
| Registries | 10 | 2024 | 8164 | 0.220 |
Why?
|
| Matrix Metalloproteinase 2 | 2 | 2023 | 461 | 0.220 |
Why?
|
| Dyspnea | 5 | 2023 | 1344 | 0.220 |
Why?
|
| Multiple Sclerosis | 1 | 2018 | 3202 | 0.210 |
Why?
|
| Receptors, Angiotensin | 4 | 2024 | 141 | 0.210 |
Why?
|
| Outpatients | 5 | 2024 | 1590 | 0.210 |
Why?
|
| Echocardiography, Doppler, Color | 2 | 2014 | 352 | 0.210 |
Why?
|
| Disease Progression | 16 | 2024 | 13463 | 0.210 |
Why?
|
| Protease Inhibitors | 2 | 2016 | 753 | 0.210 |
Why?
|
| Fumarates | 2 | 2020 | 131 | 0.210 |
Why?
|
| Immunization Schedule | 2 | 2024 | 223 | 0.200 |
Why?
|
| Brain Ischemia | 3 | 2023 | 3047 | 0.200 |
Why?
|
| Dose-Response Relationship, Drug | 12 | 2024 | 10749 | 0.200 |
Why?
|
| Myocardium | 5 | 2024 | 4690 | 0.200 |
Why?
|
| Cardiac Resynchronization Therapy | 2 | 2018 | 553 | 0.190 |
Why?
|
| Growth Differentiation Factor 15 | 2 | 2024 | 195 | 0.190 |
Why?
|
| Microscopy, Confocal | 4 | 2016 | 1966 | 0.190 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 4 | 2021 | 3217 | 0.190 |
Why?
|
| Amyloidosis, Familial | 1 | 2021 | 16 | 0.190 |
Why?
|
| Ferritins | 3 | 2024 | 597 | 0.190 |
Why?
|
| Potassium | 4 | 2021 | 1310 | 0.190 |
Why?
|
| Age Factors | 14 | 2021 | 18326 | 0.190 |
Why?
|
| Antibody Formation | 2 | 2023 | 1397 | 0.190 |
Why?
|
| Electrocardiography | 5 | 2023 | 6363 | 0.180 |
Why?
|
| Models, Statistical | 5 | 2020 | 5068 | 0.180 |
Why?
|
| Macula Lutea | 1 | 2022 | 169 | 0.180 |
Why?
|
| Ventricular Pressure | 1 | 2021 | 204 | 0.180 |
Why?
|
| Multiple Myeloma | 1 | 2018 | 5129 | 0.180 |
Why?
|
| Hospital Mortality | 9 | 2021 | 5243 | 0.180 |
Why?
|
| Amides | 2 | 2020 | 447 | 0.180 |
Why?
|
| Diabetes Complications | 3 | 2020 | 1317 | 0.180 |
Why?
|
| Placebos | 3 | 2020 | 1661 | 0.180 |
Why?
|
| North America | 6 | 2020 | 1273 | 0.180 |
Why?
|
| Internationality | 5 | 2019 | 1000 | 0.180 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2018 | 5648 | 0.180 |
Why?
|
| Placebo Effect | 2 | 2015 | 518 | 0.170 |
Why?
|
| Biological Factors | 1 | 2021 | 157 | 0.170 |
Why?
|
| Edema, Cardiac | 1 | 2019 | 19 | 0.170 |
Why?
|
| Multicenter Studies as Topic | 3 | 2021 | 1703 | 0.170 |
Why?
|
| Ultrasonography | 8 | 2021 | 5951 | 0.170 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 2019 | 69 | 0.170 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2024 | 353 | 0.170 |
Why?
|
| Vital Capacity | 2 | 2022 | 962 | 0.170 |
Why?
|
| Hemostasis, Endoscopic | 2 | 2017 | 40 | 0.170 |
Why?
|
| Metformin | 2 | 2019 | 905 | 0.170 |
Why?
|
| Diuretics, Osmotic | 1 | 2019 | 33 | 0.170 |
Why?
|
| Severity of Illness Index | 16 | 2021 | 15781 | 0.160 |
Why?
|
| Hypercholesterolemia | 2 | 2018 | 1141 | 0.160 |
Why?
|
| Drug Labeling | 1 | 2021 | 248 | 0.160 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2019 | 107 | 0.160 |
Why?
|
| Hyperaldosteronism | 1 | 2022 | 244 | 0.160 |
Why?
|
| International Classification of Diseases | 2 | 2021 | 891 | 0.160 |
Why?
|
| Cardiac Myosins | 3 | 2024 | 127 | 0.160 |
Why?
|
| Models, Cardiovascular | 1 | 2024 | 970 | 0.160 |
Why?
|
| Mannitol | 1 | 2019 | 180 | 0.160 |
Why?
|
| Heart Diseases | 2 | 2022 | 2781 | 0.160 |
Why?
|
| Sodium-Glucose Transporter 1 | 1 | 2018 | 108 | 0.160 |
Why?
|
| Body Mass Index | 8 | 2022 | 12868 | 0.150 |
Why?
|
| C-Reactive Protein | 6 | 2024 | 3809 | 0.150 |
Why?
|
| HIV Infections | 4 | 2024 | 17270 | 0.150 |
Why?
|
| Atrial Appendage | 1 | 2022 | 282 | 0.150 |
Why?
|
| Hyperemia | 1 | 2019 | 221 | 0.150 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2019 | 122 | 0.150 |
Why?
|
| Pneumonia | 3 | 2024 | 2127 | 0.150 |
Why?
|
| Kidney Transplantation | 3 | 2018 | 4214 | 0.150 |
Why?
|
| Valine | 3 | 2014 | 408 | 0.150 |
Why?
|
| Uric Acid | 2 | 2023 | 803 | 0.150 |
Why?
|
| Acute Disease | 7 | 2024 | 7225 | 0.150 |
Why?
|
| Critical Care | 2 | 2021 | 2690 | 0.150 |
Why?
|
| Patient Readmission | 3 | 2024 | 3241 | 0.150 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2023 | 517 | 0.150 |
Why?
|
| Vasodilator Agents | 4 | 2023 | 973 | 0.150 |
Why?
|
| Canrenone | 1 | 2017 | 5 | 0.150 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2018 | 206 | 0.150 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2024 | 1044 | 0.140 |
Why?
|
| Intestinal Absorption | 1 | 2018 | 400 | 0.140 |
Why?
|
| Cardiac Volume | 1 | 2018 | 199 | 0.140 |
Why?
|
| Retinal Vessels | 2 | 2022 | 836 | 0.140 |
Why?
|
| Creatinine | 6 | 2021 | 1892 | 0.140 |
Why?
|
| Virus Diseases | 1 | 2023 | 719 | 0.140 |
Why?
|
| Ileum | 3 | 2020 | 556 | 0.140 |
Why?
|
| Adiposity | 2 | 2018 | 1856 | 0.140 |
Why?
|
| Apolipoprotein E4 | 1 | 2021 | 706 | 0.140 |
Why?
|
| Sleep Apnea, Obstructive | 3 | 2015 | 1851 | 0.140 |
Why?
|
| Myocardial Contraction | 3 | 2024 | 1516 | 0.140 |
Why?
|
| Estradiol | 1 | 2024 | 1933 | 0.140 |
Why?
|
| Blood Urea Nitrogen | 1 | 2017 | 186 | 0.140 |
Why?
|
| Area Under Curve | 2 | 2018 | 1632 | 0.140 |
Why?
|
| Cross-Sectional Studies | 14 | 2024 | 25924 | 0.140 |
Why?
|
| Hypoglycemia | 2 | 2022 | 881 | 0.140 |
Why?
|
| Digoxin | 2 | 2022 | 246 | 0.140 |
Why?
|
| Pleural Effusion | 1 | 2020 | 342 | 0.140 |
Why?
|
| Duodenal Diseases | 1 | 2017 | 99 | 0.140 |
Why?
|
| Retrospective Studies | 26 | 2023 | 79984 | 0.140 |
Why?
|
| beta Carotene | 1 | 2018 | 523 | 0.140 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 3 | 2023 | 150 | 0.130 |
Why?
|
| Hyperglycemia | 3 | 2020 | 1368 | 0.130 |
Why?
|
| Proton Pump Inhibitors | 1 | 2021 | 529 | 0.130 |
Why?
|
| Blood Pressure Determination | 1 | 2020 | 634 | 0.130 |
Why?
|
| Multivariate Analysis | 10 | 2020 | 12047 | 0.130 |
Why?
|
| Hemoglobins | 2 | 2023 | 1518 | 0.130 |
Why?
|
| Esophageal Diseases | 1 | 2017 | 168 | 0.130 |
Why?
|
| Russia | 4 | 2018 | 381 | 0.130 |
Why?
|
| Retinal Artery | 1 | 2016 | 109 | 0.130 |
Why?
|
| Troponin | 1 | 2019 | 500 | 0.130 |
Why?
|
| Health Status Disparities | 2 | 2018 | 1821 | 0.130 |
Why?
|
| Gout | 1 | 2023 | 618 | 0.130 |
Why?
|
| Stomach Diseases | 1 | 2017 | 133 | 0.130 |
Why?
|
| Vascular Resistance | 2 | 2015 | 930 | 0.130 |
Why?
|
| Pandemics | 5 | 2023 | 8600 | 0.130 |
Why?
|
| Chi-Square Distribution | 6 | 2017 | 3415 | 0.130 |
Why?
|
| Therapeutics | 1 | 2015 | 113 | 0.130 |
Why?
|
| Glucose Tolerance Test | 1 | 2018 | 1173 | 0.130 |
Why?
|
| Myocardial Ischemia | 2 | 2023 | 2109 | 0.120 |
Why?
|
| Calcinosis | 1 | 2024 | 1467 | 0.120 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2015 | 105 | 0.120 |
Why?
|
| Longevity | 2 | 2020 | 1050 | 0.120 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2020 | 570 | 0.120 |
Why?
|
| Prehypertension | 1 | 2015 | 63 | 0.120 |
Why?
|
| Diabetic Neuropathies | 1 | 2018 | 405 | 0.120 |
Why?
|
| Heart Valve Diseases | 1 | 2022 | 1033 | 0.120 |
Why?
|
| Pulmonary Artery | 1 | 2023 | 1916 | 0.120 |
Why?
|
| Young Adult | 17 | 2024 | 58755 | 0.120 |
Why?
|
| Prevalence | 11 | 2020 | 15640 | 0.120 |
Why?
|
| Guidelines as Topic | 1 | 2021 | 1384 | 0.120 |
Why?
|
| Cardiomyopathy, Restrictive | 1 | 2015 | 61 | 0.120 |
Why?
|
| Insulin | 3 | 2018 | 6578 | 0.120 |
Why?
|
| Alcohol Drinking | 3 | 2019 | 4019 | 0.120 |
Why?
|
| Exercise | 4 | 2019 | 5788 | 0.120 |
Why?
|
| Captopril | 1 | 2015 | 265 | 0.120 |
Why?
|
| Lung | 7 | 2023 | 9973 | 0.120 |
Why?
|
| Aging | 3 | 2020 | 8654 | 0.120 |
Why?
|
| Hypertension, Pulmonary | 2 | 2015 | 1565 | 0.120 |
Why?
|
| Pre-Eclampsia | 1 | 2023 | 1226 | 0.120 |
Why?
|
| Echocardiography, Three-Dimensional | 2 | 2018 | 606 | 0.110 |
Why?
|
| Insulin Resistance | 2 | 2021 | 3941 | 0.110 |
Why?
|
| Ventricular Fibrillation | 1 | 2017 | 537 | 0.110 |
Why?
|
| Hemagglutination Inhibition Tests | 2 | 2024 | 85 | 0.110 |
Why?
|
| Aortic Valve | 1 | 2024 | 1950 | 0.110 |
Why?
|
| Patient Dropouts | 1 | 2016 | 412 | 0.110 |
Why?
|
| Endoscopy, Digestive System | 1 | 2016 | 351 | 0.110 |
Why?
|
| Hemodynamics | 4 | 2021 | 4156 | 0.110 |
Why?
|
| Tissue Survival | 1 | 2014 | 119 | 0.110 |
Why?
|
| Delivery, Obstetric | 1 | 2021 | 931 | 0.110 |
Why?
|
| Ankle Brachial Index | 1 | 2014 | 159 | 0.110 |
Why?
|
| Geriatric Assessment | 2 | 2019 | 1402 | 0.110 |
Why?
|
| Electric Countershock | 1 | 2017 | 533 | 0.110 |
Why?
|
|